<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph F Merola, MD, MMSc, FAAD, FACR</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H30497559"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sweet syndrome (acute febrile neutrophilic dermatosis) is an uncommon inflammatory disorder characterized by the abrupt appearance of painful, edematous, and erythematous papules, plaques, or nodules on the skin. Fever and leukocytosis frequently accompany the cutaneous lesions. In addition, involvement of the eyes, musculoskeletal system, and internal organs may occur.</p><p>The epidemiology, clinical features, and diagnosis of Sweet syndrome will be discussed here. Information on the treatment and prognosis of Sweet syndrome and an overview of other neutrophilic dermatoses are available separately. (See  <a class="medical medical_review" href="/d/html/86567.html" rel="external">"Sweet syndrome (acute febrile neutrophilic dermatosis): Management and prognosis"</a> and  <a class="medical medical_review" href="/d/html/5571.html" rel="external">"Neutrophilic dermatoses"</a>.)</p><p class="headingAnchor" id="H1950250"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Sweet syndrome was first described by Dr. Robert Douglas Sweet in 1964, who documented the development of an acute inflammatory skin eruption with fever and leukocytosis in eight women, several of whom had preceding upper respiratory or gastrointestinal infections [<a href="#rid1">1</a>]. Since then, Sweet syndrome has been observed in association with a broad range of disorders. As a result, some authors divide Sweet syndrome into three subtypes based upon etiology:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classical Sweet syndrome</strong></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy-associated Sweet syndrome</strong></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced Sweet syndrome</strong></p><p></p><p class="headingAnchor" id="H1950288"><span class="h2">Classical Sweet syndrome</span><span class="headingEndMark"> — </span>Classical Sweet syndrome (also referred to as idiopathic Sweet syndrome) constitutes the majority of cases of Sweet syndrome and is defined as Sweet syndrome that meets the established diagnostic criteria and is not associated with malignancy or drug exposure  (<a class="graphic graphic_table graphicRef85940" href="/d/graphic/85940.html" rel="external">table 1</a>) [<a href="#rid2">2</a>]. Classical Sweet syndrome may occur in the setting of a variety of medical conditions. The conditions that are most frequently associated with classical Sweet syndrome are listed below [<a href="#rid2">2-5</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> (particularly upper respiratory tract and gastrointestinal infections; Sweet syndrome usually develops one to three weeks after infection [<a href="#rid6">6</a>])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory bowel disease</strong> (Crohn disease and ulcerative colitis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong></p><p></p><p>Less frequent and less definitive associations exist with other infections (eg, human immunodeficiency virus [HIV], tuberculosis, chlamydia, viral hepatitis), primary immunodeficiencies, autoimmune conditions (eg, Behçet syndrome, relapsing polychondritis, rheumatoid arthritis, sarcoidosis, autoimmune thyroid disease, connective tissue disorders including systemic lupus erythematosus and dermatomyositis), and VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome [<a href="#rid2">2,7</a>]. Further studies are necessary to determine the strength of the relationships between Sweet syndrome and these diseases.</p><p>VEXAS syndrome is an autoinflammatory syndrome that has been described in adult males. Dermatologic manifestations are common and were documented in 126 of 141 patients with VEXAS syndrome (89 percent) identified in a 2022 review of the literature [<a href="#rid8">8</a>]. Sweet syndrome-like lesions (tender, erythematous or violaceous nodules) appear to be the most frequent cutaneous finding. Other dermatologic features include cartilaginous involvement with aural and nasal chondritis, cutaneous vasculitis, and periorbital angioedema [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/122508.html" rel="external">"Autoinflammatory diseases mediated by NFkB and/or aberrant TNF activity", section on 'Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome'</a>.)</p><p class="headingAnchor" id="H1950295"><span class="h2">Malignancy-associated Sweet syndrome</span><span class="headingEndMark"> — </span>Malignancy-associated Sweet syndrome accounts for a significant portion of cases of Sweet syndrome [<a href="#rid9">9-12</a>]. A 1993 review of several retrospective series found that 25 of 118 patients with Sweet syndrome (21 percent) had a hematologic or solid tumor malignancy [<a href="#rid9">9</a>]. In children, malignancy-associated Sweet syndrome appears to primarily occur in children over the age of three years [<a href="#rid10">10</a>]. Rare cases of malignancy-associated Sweet syndrome have been reported in infants [<a href="#rid13">13,14</a>]. </p><p>Sweet syndrome may precede, follow, or appear concurrently with a malignancy [<a href="#rid9">9,15-47</a>]. In patients with previous histories of cancer, the development of Sweet syndrome may portend disease recurrence [<a href="#rid2">2</a>].</p><p>Sweet syndrome is more likely to occur in association with hematologic malignancies than solid tumor cancers [<a href="#rid12">12,47-49</a>]. In a 1998 review of 79 patients with malignancies and Sweet syndrome, 69 (87 percent) had hematologic malignancies and 12 had solid tumors (15 percent), including two patients who had both acute myelogenous leukemia (AML) and prostate cancer [<a href="#rid50">50</a>]. AML is the malignancy most frequently associated with Sweet syndrome. In the review, AML accounted for 42 percent of the hematologic malignancies and myeloproliferative disorders constituted the second most common category of malignancy (22 percent) [<a href="#rid50">50</a>]. Among solid tumors, carcinomas of the genitourinary organs, breast, and gastrointestinal tract are most frequently linked with Sweet syndrome [<a href="#rid9">9,51</a>]. </p><p>Certain patient characteristics may be associated with increased risk for malignancy. Retrospective studies of patients with Sweet syndrome have found patients with older age, anemia, thrombocytopenia, leukopenia, and lack of arthralgias more likely to have malignancy-associated Sweet syndrome [<a href="#rid47">47,49</a>].</p><p>In addition, risk for malignancy may be elevated in patients with the histiocytoid or subcutaneous histologic variant of Sweet syndrome. In a retrospective study of 62 patients with a histopathologic diagnosis of Sweet syndrome, 12 of 22 patients (55 percent) with histiocytoid Sweet syndrome had an associated hematologic malignancy compared with 10 of 40 patients (25 percent) with classical Sweet syndrome [<a href="#rid52">52</a>]. Myelodysplastic syndrome was the most common malignancy in patients with histiocytoid Sweet syndrome, occurring in 32 percent of these patients compared with 3 percent of patients with classical Sweet syndrome. In a separate retrospective study in which 36 of 83 patients (44 percent) with Sweet syndrome had malignancy-associated disease, histiocytoid and subcutaneous histopathologies were associated with malignancy [<a href="#rid49">49</a>]. All 13 patients with one of these histologic variants had a concurrent malignancy. (See <a class="local">'Pathology findings'</a> below.)</p><p class="headingAnchor" id="H1950361"><span class="h2">Drug-induced Sweet syndrome</span><span class="headingEndMark"> — </span>Multiple drugs may contribute to Sweet syndrome [<a href="#rid48">48,53-69</a>]. A list of drugs that have been associated with Sweet syndrome is provided in a table  (<a class="graphic graphic_table graphicRef85942" href="/d/graphic/85942.html" rel="external">table 2</a>). Granulocyte-colony stimulating factor (G-CSF) is the most widely reported contributory medication [<a href="#rid56">56</a>].</p><p>The development of neutrophilic dermatoses as a consequence of checkpoint inhibitor immunotherapy, including Sweet syndrome secondary to <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> therapy, has been reported [<a href="#rid70">70</a>]. A drug-induced increase in immunologic activity is thought to contribute. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Dermatologic and mucosal toxicity'</a>.)</p><p>Sweet syndrome usually develops approximately two weeks after drug exposure in patients who lack a prior history of exposure to the inciting drug [<a href="#rid71">71</a>]. Recurrence of the syndrome usually develops after re-exposure to the inciting drug [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H30497566"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Although individuals between the ages of 30 and 60 most frequently develop classical Sweet syndrome, infants, children, and older adults may also be affected [<a href="#rid2">2,7,10</a>]. The age of onset tends to be older among patients with malignancy-associated Sweet syndrome. In a retrospective study of patients seen at a single academic center, the average age at diagnosis was 68 years among 27 patients with malignancy-associated Sweet syndrome compared with 51 years among 41 patients with classic Sweet syndrome [<a href="#rid48">48</a>]. The mean age for reported pediatric cases is slightly over five years [<a href="#rid10">10</a>].</p><p>The sex distribution varies with the subtype of Sweet syndrome and patient age. In classical Sweet syndrome, 80 percent of patients are women, whereas the proportion of women is lower in other clinical variants [<a href="#rid2">2</a>]. In Sweet syndrome associated with drugs, solid tumors, and hematologic malignancies, the percentage of patients who are women is estimated to be 70, 60, and 50 percent [<a href="#rid2">2</a>]. The female predominance in Sweet syndrome does not appear to apply to children. In a systematic review that included 66 reports of children with Sweet syndrome, the disorder was twice as likely to occur in males among children under the age of three [<a href="#rid10">10</a>]. In children over the age of three, the sex distribution was equal.</p><p>There is no obvious racial predilection in Sweet syndrome. </p><p class="headingAnchor" id="H30497573"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of Sweet syndrome is not well understood. Factors theorized to contribute to the development of this disorder include hypersensitivity reactions, cytokine dysregulation, and genetic susceptibility:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity reaction </strong>– An immune reaction to bacterial, viral, tumor, or other antigens could influence the development of Sweet syndrome through stimulating the production of cytokines that promote neutrophil activation and infiltration [<a href="#rid72">72</a>]. The positive response to systemic glucocorticoids and reports of improvement in Sweet syndrome following treatment of bacterial infections or malignancies offer some support to this theory [<a href="#rid72">72-74</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytokine dysregulation </strong>– Certain cytokines and chemokines may contribute to the initiation and propagation of the inflammatory response in Sweet syndrome. A role for granulocyte colony-stimulating factor (G-CSF) is compelling, since G-CSF increases circulating neutrophils and exogenous G-CSF is a common cause of drug-induced Sweet syndrome [<a href="#rid56">56</a>]. Moreover, higher serum levels of G-CSF have been detected in patients with active Sweet syndrome than in patients with inactive disease [<a href="#rid75">75</a>]. Increased production of G-CSF by tumor cells has also been proposed as a potential factor in malignancy-associated disease [<a href="#rid2">2,76</a>]. </p><p></p><p class="bulletIndent1">Other cytokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukins (eg, IL-1, IL-3, IL-6, and IL-8) are postulated to play roles in Sweet syndrome [<a href="#rid77">77-80</a>]. In a study of eight patients with Sweet syndrome, serum levels of Th1 cytokines, including IL-1 alpha, IL-1 beta, IL-2, and interferon-gamma were elevated, whereas levels of IL-4, a Th2 cytokine remained normal [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic susceptibility </strong>– Abnormalities in chromosome 3q have been reported in association with Sweet syndrome in a few patients [<a href="#rid33">33,82-84</a>]. HLA-B54 has been linked to Sweet syndrome in Japanese patients [<a href="#rid85">85,86</a>]. In addition, mutations in the <em>MEFV</em> gene, a gene associated with familial Mediterranean fever, have been detected in two patients with myelodysplastic syndrome and cutaneous findings consistent with Sweet syndrome [<a href="#rid87">87</a>].</p><p></p><p>Antibodies to neutrophilic cytoplasmic antigens have been detected in some patients with Sweet syndrome [<a href="#rid84">84,88</a>]. However, a pathogenic role for these antibodies has not been established. Further study is necessary to clarify the mechanisms that lead to the development of Sweet syndrome.</p><p class="headingAnchor" id="H30497594"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In addition to the abrupt onset of the painful inflammatory papules, plaques, and nodules that characterize Sweet syndrome, additional clinical features may develop. An overview of the mucocutaneous and extracutaneous manifestations of Sweet syndrome is provided below. The differences in the clinical and laboratory features of the subtypes of Sweet syndrome are provided in a table  (<a class="graphic graphic_table graphicRef85941" href="/d/graphic/85941.html" rel="external">table 3</a>). </p><p class="headingAnchor" id="H1955675"><span class="h2">Cutaneous</span><span class="headingEndMark"> — </span>The cutaneous lesions of Sweet syndrome typically present as tender, edematous, and inflamed papules, plaques, and nodules  (<a class="graphic graphic_picture graphicRef74393 graphicRef85644 graphicRef85645 graphicRef85646 graphicRef79243 graphicRef85647" href="/d/graphic/74393.html" rel="external">picture 1A-F</a>). Lesions are usually several millimeters to several centimeters in diameter and exhibit a brightly erythematous or violaceous color.</p><p>The inflammatory papules and plaques often exhibit a mamillated surface [<a href="#rid89">89</a>]. Significant superficial dermal edema leading to a pseudovesicular quality is common. Pustules may also be present. In some cases, the skin lesions develop a central yellowish hue resulting in a targetoid appearance. </p><p>The distribution of the cutaneous eruption is often asymmetrical. The upper extremities appear to be the most common site of involvement [<a href="#rid2">2,48</a>]. Lesions also frequently develop on the trunk, lower extremities, head, and neck [<a href="#rid48">48</a>].</p><p>Patients often describe the pain associated with cutaneous lesions in Sweet syndrome as tenderness or a burning sensation. Although our experience suggests that pruritus rarely occurs, a retrospective study of 77 patients with Sweet syndrome found documentation of pruritus in 18 percent of patients [<a href="#rid48">48</a>]. </p><p>Less common presentations of Sweet syndrome include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bullous Sweet syndrome </strong>– Bullous Sweet syndrome is an uncommon presentation of Sweet syndrome in which vesicles and flaccid bullae overly erythematous to violaceous plaques  (<a class="graphic graphic_picture graphicRef62314 graphicRef50526" href="/d/graphic/62314.html" rel="external">picture 2A-B</a>) [<a href="#rid72">72</a>]. Ulceration resembling pyoderma gangrenosum may occur in bullous Sweet syndrome; this manifestation most commonly occurs in the setting of hematologic malignancy [<a href="#rid12">12,30,89</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subcutaneous Sweet syndrome </strong>– In subcutaneous Sweet syndrome, the site of neutrophilic infiltration is in the subcutaneous fat, rather than the dermis (see <a class="local">'Pathology findings'</a> below). This results in the development of erythematous nodules with minimal superficial change. The nodules are usually 2 to 3 cm in diameter [<a href="#rid90">90</a>], and the extremities are common sites of involvement. Subcutaneous Sweet syndrome can closely resemble erythema nodosum, particularly when it involves the lower legs  (<a class="graphic graphic_picture graphicRef63142" href="/d/graphic/63142.html" rel="external">picture 3</a>) [<a href="#rid91">91</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutrophilic dermatosis of the dorsal hands </strong>– Neutrophilic dermatosis of the dorsal hands (also known as pustular vasculitis of the dorsal hands) is a localized disorder that may be on a continuum with Sweet syndrome [<a href="#rid92">92</a>]. Affected patients develop inflammatory and pustular plaques on the dorsal surfaces of the hands  (<a class="graphic graphic_picture graphicRef69295" href="/d/graphic/69295.html" rel="external">picture 4</a>). Neutrophilic dermatosis of the dorsal hands is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/5571.html" rel="external">"Neutrophilic dermatoses", section on 'Neutrophilic dermatosis of the dorsal hands'</a>.)</p><p></p><p>In addition, patients with Sweet syndrome resembling necrotizing fasciitis (necrotizing Sweet syndrome) have been reported [<a href="#rid93">93,94</a>]. Patients present with fever accompanied by expanding erythematous to violaceous plaques. Underlying risk factors for Sweet syndrome (exposure to G-CSF, malignancy, and/or HIV infection) may be present. (See  <a class="medical medical_review" href="/d/html/5571.html" rel="external">"Neutrophilic dermatoses", section on 'Necrotizing neutrophilic dermatoses'</a> and  <a class="medical medical_review" href="/d/html/7662.html" rel="external">"Necrotizing soft tissue infections", section on 'Necrotizing fasciitis'</a>.)</p><p>Large cellulitis-like plaques may be another rare clinical presentation of Sweet syndrome. The term "giant cellulitis-like Sweet syndrome" was used to refer to the development of large infiltrated inflammatory plaques and bullae in three patients who met diagnostic criteria for Sweet syndrome [<a href="#rid95">95</a>]. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p>The phenomenon of <strong>pathergy</strong> (lesion development at sites of cutaneous injury) may occur in patients with Sweet syndrome [<a href="#rid10">10</a>]. Even minor trauma, such as that obtained with a needle stick, may result in the development of skin lesions.</p><p class="headingAnchor" id="H704799"><span class="h2">Oral cavity</span><span class="headingEndMark"> — </span>Oral involvement is uncommon in classical Sweet syndrome. However, approximately 12 percent of patients with Sweet syndrome related to hematologic malignancies develop oral ulcers as a disease manifestation, particularly on the buccal mucosa or tongue  (<a class="graphic graphic_table graphicRef85941" href="/d/graphic/85941.html" rel="external">table 3</a>) [<a href="#rid2">2</a>]. Additional reported oral findings include bullae, vesicles, gingival hyperplasia, necrotizing ulcerative periodontitis, nodules, papules, pustules, and tongue swelling [<a href="#rid2">2,96</a>].</p><p class="headingAnchor" id="H704827"><span class="h2">Associated symptoms</span><span class="headingEndMark"> — </span>The name "acute febrile neutrophilic dermatosis" reflects the frequent presence of fever &gt;38°C in Sweet syndrome. Patients with drug-induced Sweet syndrome are almost always febrile, but fever may spare 10 to 20 percent of patients with classical or malignancy-associated disease  (<a class="graphic graphic_table graphicRef85941" href="/d/graphic/85941.html" rel="external">table 3</a>) [<a href="#rid2">2</a>]. Arthralgias, malaise, headache, and myalgias are additional symptoms that frequently occur in Sweet syndrome [<a href="#rid6">6,89</a>]. </p><p class="headingAnchor" id="H30497601"><span class="h2">Extracutaneous disease</span><span class="headingEndMark"> — </span>Neutrophilic infiltration of other organ systems, such as the eye, muscles, lung, bone, liver, spleen, heart, kidneys, central nervous system, and gastrointestinal system may occur in Sweet syndrome, resulting in signs or symptoms specific to the extracutaneous site of inflammation. Ocular inflammation is a common extracutaneous manifestation; ocular involvement occurs in 17 to 72 percent of patients with the classical variant [<a href="#rid2">2</a>]. Examples of ocular manifestations include conjunctivitis, episcleritis, scleritis, limbal nodules, peripheral ulcerative keratitis, iritis, glaucoma, dacryoadenitis, and choroiditis [<a href="#rid97">97,98</a>]. The musculoskeletal system is another frequent site of extracutaneous involvement, manifesting as arthralgias, arthritis, and myalgias. </p><p>Examples of uncommon extracutaneous manifestations of Sweet syndrome include [<a href="#rid6">6,89</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system </strong>– Encephalitis, aseptic meningitis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular system </strong>– Myocarditis, aortitis and aortic stenosis, coronary artery occlusion</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary system </strong>– Neutrophilic alveolitis, pleural effusions, airway obstruction</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver </strong>– Hepatitis, hepatomegaly</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intestines </strong>– Neutrophilic inflammation of intestines</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spleen </strong>– Splenomegaly</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidneys </strong>– Mesangial glomerulonephritis, hematuria, proteinuria</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone </strong>– Sterile osteomyelitis</p><p></p><p>The development of systemic inflammatory response syndrome (SIRS) in the setting of Sweet syndrome has also been reported [<a href="#rid18">18,99-101</a>].</p><p class="headingAnchor" id="H691464001"><span class="h2">Associated laboratory findings</span><span class="headingEndMark"> — </span>Peripheral leukocytosis with neutrophilia is the most common laboratory abnormality in patients with Sweet syndrome. Neutrophilia is present in the vast majority of patients with classical Sweet syndrome, and in a significant proportion of patients with malignancy-associated and drug-induced disease  (<a class="graphic graphic_table graphicRef85941" href="/d/graphic/85941.html" rel="external">table 3</a>). Nonspecific inflammatory markers such as the erythrocyte sedimentation rate and C-reactive protein level are also frequently elevated in patients with Sweet syndrome. </p><p>Anemia and platelet abnormalities are commonly seen in Sweet syndrome related to malignancy or drugs, but are infrequently detected in patients with classical Sweet syndrome  (<a class="graphic graphic_table graphicRef85941" href="/d/graphic/85941.html" rel="external">table 3</a>) [<a href="#rid2">2,48</a>]. Abnormalities on the complete metabolic panel and urinalysis may indicate hepatic or renal involvement.</p><p class="headingAnchor" id="H1955716"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of Sweet syndrome is based upon the recognition of consistent clinical and laboratory findings as well as the exclusion of disorders that may present with similar clinical features. A rapid and dramatic response to systemic glucocorticoid therapy also supports the diagnosis. </p><p class="headingAnchor" id="H705447"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>A revised set of diagnostic criteria [<a href="#rid102">102</a>] based upon criteria outlined in 1986 [<a href="#rid54">54</a>] is widely used for the diagnosis of Sweet syndrome  (<a class="graphic graphic_table graphicRef85940" href="/d/graphic/85940.html" rel="external">table 1</a>). Both major criteria and two of four minor criteria are required to establish a diagnosis of classical or malignancy-associated Sweet syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major criteria</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abrupt onset of painful erythematous plaques or nodules</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histopathologic evidence of a dense neutrophilic infiltrate without evidence of leukocytoclastic vasculitis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Minor criteria</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pyrexia &gt;38°C</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Association with underlying hematologic or visceral malignancy, inflammatory disease or pregnancy, <strong>or</strong> preceded by upper respiratory infection, gastrointestinal infection, or vaccination</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Excellent response to treatment with systemic glucocorticoids or potassium iodide</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal laboratory values at presentation (three of four of the following: erythrocyte sedimentation rate &gt;20 mm/hour, positive C-reactive protein, &gt;8000 leukocytes, &gt;70 percent neutrophils)</p><p></p><p>A separate set of criteria has been proposed for drug-induced Sweet syndrome  (<a class="graphic graphic_table graphicRef85940" href="/d/graphic/85940.html" rel="external">table 1</a>) [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H705454"><span class="h2">Clinical assessment</span><span class="headingEndMark"> — </span>The clinical assessment of the patient offers valuable clues for diagnosis. The history may reveal a rapid onset of skin lesions and the presence of associated symptoms (eg, painful skin lesions, fever, malaise), findings that are compatible with Sweet syndrome. In addition, the knowledge that a patient has a condition known to occur in association with Sweet syndrome (eg, recent infection, malignancy, pregnancy, or inflammatory bowel disease) raises clinical suspicion for the diagnosis. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Classification'</a> above.)</p><p>A complete physical examination that includes surveillance of the entire skin surface should be performed. This aids in determining whether the morphology and distribution of skin lesions is consistent with Sweet syndrome and allows for an assessment of the extent of cutaneous disease as well as an evaluation for signs of extracutaneous involvement. </p><p class="headingAnchor" id="H12627044"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>In patients in whom the clinical findings suggest the possibility of Sweet syndrome, a skin biopsy and select laboratory tests are indicated.</p><p class="headingAnchor" id="H2457524"><span class="h3">Biopsy</span><span class="headingEndMark"> — </span>The detection of consistent histologic findings is a major diagnostic criterion for Sweet syndrome  (<a class="graphic graphic_table graphicRef85940" href="/d/graphic/85940.html" rel="external">table 1</a>) (see <a class="local">'Diagnostic criteria'</a> above). Thus, a skin biopsy should be performed whenever feasible.</p><p class="headingAnchor" id="H12627162"><span class="h4">Procedure</span><span class="headingEndMark"> — </span>In patients with inflammatory papules or plaques, a 4 mm punch biopsy is usually sufficient for obtaining a tissue specimen for histologic examination. Because infection may closely resemble Sweet syndrome, microbial pathology stains should be performed. In addition, we obtain a second 4 mm punch biopsy for bacterial, fungal, and mycobacterial cultures. If pustules are present, a swab specimen can also be sent for culture.</p><p>In patients with nodules suggestive of subcutaneous Sweet syndrome (a variant in which the pathologic process is primarily located in the subcutaneous fat), an excisional biopsy is preferred because it provides a more generous sample of the subcutaneous fat, which may facilitate the interpretation of the histologic findings. As above, a portion of the tissue specimen should be sent for microbial cultures. (See <a class="local">'Pathology findings'</a> below and  <a class="medical medical_review" href="/d/html/5577.html" rel="external">"Skin biopsy techniques"</a> and  <a class="medical medical_review" href="/d/html/13780.html" rel="external">"Panniculitis: Recognition and diagnosis", section on 'Biopsy'</a>.)</p><p class="headingAnchor" id="H2457599"><span class="h4">Pathology findings</span><span class="headingEndMark"> — </span>The characteristic histologic features of Sweet syndrome include [<a href="#rid103">103</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prominent edema in the superficial dermis</p><p class="bulletIndent1"><span class="glyph">●</span>Dense infiltrate of neutrophils in the upper and mid-dermis with sparing of the epidermis  (<a class="graphic graphic_picture graphicRef66680" href="/d/graphic/66680.html" rel="external">picture 5</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Leukocytoclasis</p><p class="bulletIndent1"><span class="glyph">●</span>Endothelial swelling </p><p class="bulletIndent1"><span class="glyph">●</span>Absence of vasculitis (see below)</p><p></p><p>A few eosinophils may also be present. Older lesions may exhibit small numbers of lymphocytes or macrophages [<a href="#rid103">103</a>].</p><p>Although the absence of vasculitis is considered a characteristic feature of Sweet syndrome, the identification of vasculitis in a biopsy specimen does not rule out the diagnosis. In a retrospective study of skin biopsies from 21 patients with Sweet syndrome, vasculitis was identified in specimens from 6 patients (29 percent) [<a href="#rid104">104</a>]. The vasculitis seen in Sweet syndrome may be a secondary phenomenon related to the release of noxious products from neutrophils [<a href="#rid104">104</a>]. </p><p>Pathologic variants of Sweet syndrome include subcutaneous Sweet syndrome and histiocytoid Sweet syndrome [<a href="#rid105">105-110</a>]. Subcutaneous Sweet syndrome is characterized by a dense neutrophilic infiltrate in the subcutaneous tissue. Although lobular inflammation is usually most prominent, both septa and lobules may be involved [<a href="#rid90">90</a>]. In histiocytoid Sweet syndrome, the dermal inflammatory infiltrate is primarily composed of histiocyte-like immature myeloid cells [<a href="#rid111">111</a>]. Histiocytoid Sweet syndrome may be difficult to distinguish from leukemia cutis [<a href="#rid112">112</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H705462"><span class="h3">Serologic and other tests</span><span class="headingEndMark"> — </span>Laboratory evaluation is useful for identifying findings consistent with Sweet syndrome (eg, leukocytosis) and signs of associated diseases or extracutaneous involvement. Our routine laboratory work-up for patients with suspected Sweet syndrome includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with platelets and differential</p><p class="bulletIndent1"><span class="glyph">●</span>Complete metabolic panel</p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocyte sedimentation rate or C-reactive protein </p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in women of childbearing age</p><p></p><p>Additional laboratory studies are ordered based upon suspicion for specific sites of extracutaneous disease and associated underlying disorders. For example, patients with pulmonary symptoms, pleuritis, or hypoxia should have a chest radiograph to look for signs of pulmonary involvement. Examples of additional investigations for an underlying disorder include searches for evidence of recent streptococcal infection or an occult malignancy. </p><p class="headingAnchor" id="H565690"><span class="h2">Evaluation for malignancy</span><span class="headingEndMark"> — </span>Malignancy testing should only be considered in the setting of reasonable clinical suspicion for an underlying malignancy (eg, constitutional symptoms such as weight loss) and the absence of another explanation for a Sweet syndrome diagnosis (ie, pregnancy, drug exposure, recent infection, inflammatory bowel disease, rheumatoid arthritis, etc.). The screening for malignancy should begin with age-appropriate cancer screening guidelines. Some experts have proposed a work-up based upon the most common malignancies reported in association with Sweet syndrome [<a href="#rid9">9</a>]. This includes a physical examination that incorporates thyroid and lymph node examinations, as well as breast, cervical, uterine, and ovarian cancer screening in women and prostate and testicular examinations in men. Additional tests considered by these authors include a carcinoembryonic antigen level, colon cancer screening, and a chest radiograph. Other authors have suggested the use of chest, abdomen, and pelvis CT imaging or PET-CT imaging to evaluate for malignancy in patients with paraneoplastic conditions and reasonable suspicion for a malignancy of unknown source; this is similar to the literature for malignancy work-up of dermatomyositis, which is largely driven by expert opinion [<a href="#rid113">113-115</a>].</p><p class="headingAnchor" id="H705609"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H1570541890"><span class="h2">Lesion morphology</span><span class="headingEndMark"> — </span>The clinical differential diagnosis of Sweet syndrome is dependent upon lesion morphology. Data obtained from the clinical history, physical examination, pathology findings, and microbial studies are useful for distinguishing between Sweet syndrome and other conditions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythematous, edematous plaques</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous infection (bacterial, fungal, and mycobacterial) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urticaria and urticarial vasculitis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other neutrophilic dermatoses (eg, pyoderma gangrenosum, neutrophilic eccrine hidradenitis, Behçet syndrome, cutaneous metastatic Crohn disease)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drug eruptions</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Halogenoderma (eg, bromoderma, iododerma)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nodules (including subcutaneous Sweet syndrome)</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous infection (eg, deep fungal infection, Majocchi's granuloma, atypical mycobacterial infection)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malignancy (eg, lymphoma cutis, leukemia cutis, metastatic carcinoma)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subcutaneous sarcoidosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vasculitis (particularly medium-vessel vasculitis such as cutaneous polyarteritis nodosa) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Erythema nodosum</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bullous lesions</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bullous pyoderma gangrenosum </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bullous leukocytoclastic vasculitis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autoimmune bullous diseases (eg, bullous pemphigoid, bullous systemic lupus erythematosus, inflammatory epidermolysis bullosa acquisita, linear IgA bullous dermatosis)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infection with bullous and hemorrhagic or necrotic changes (eg, bullous cellulitis, vessel invasive infections such as aspergillosis, ecthyma gangrenosum). </p><p></p><p class="headingAnchor" id="H243455313"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Infection is one of the most important disorders to consider in the patient with clinical and/or histologic findings suggestive of Sweet syndrome. As in Sweet syndrome, fever, leukocytosis, and cutaneous lesions characterized by neutrophil-dense infiltrates may occur in bacterial sepsis. In addition, the lesions of Sweet syndrome can resemble local bacterial, fungal, or atypical mycobacterial infections.</p><p class="headingAnchor" id="H3547477701"><span class="h2">Leukemia cutis</span><span class="headingEndMark"> — </span>The findings of a retrospective study in which fluorescence in situ hybridization (FISH) was performed on preserved cutaneous specimens from five of six patients given a diagnosis of hematologic malignancy-associated histiocytoid Sweet syndrome suggest that the clinicopathologic findings of histiocytoid Sweet syndrome may be particularly difficult to distinguish from leukemia cutis [<a href="#rid112">112</a>]. Cytogenic abnormalities in lesional skin were identical to those found in prior bone marrow biopsy specimens in four of the five patients, suggesting that these four patients may have actually had leukemia cutis. Additional studies are necessary to determine the role FISH analysis should play in differentiating histiocytoid Sweet syndrome and leukemia cutis.</p><p class="headingAnchor" id="H3380028"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Sweet syndrome (acute febrile neutrophilic dermatosis) is an inflammatory disorder characterized by the presence of inflammatory papules, plaques, or nodules on the skin, systemic symptoms, and neutrophilic infiltration of the skin. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification </strong>– Sweet syndrome is often divided into three categories based on etiology: classical Sweet syndrome, malignancy-associated Sweet syndrome, and drug-induced Sweet syndrome  (<a class="graphic graphic_table graphicRef85941" href="/d/graphic/85941.html" rel="external">table 3</a>). (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1">Classical Sweet syndrome includes cases of Sweet syndrome that are not associated with malignancy or drug exposure. The most common causes of malignancy-associated Sweet syndrome and drug-induced Sweet syndrome are acute myelogenous leukemia and granulocyte-colony stimulating factor (G-CSF), respectively. (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– The cutaneous lesions of Sweet syndrome are typically painful, erythematous to violaceous papules and plaques  (<a class="graphic graphic_picture graphicRef74393 graphicRef85644 graphicRef85645 graphicRef85646 graphicRef79243 graphicRef85647" href="/d/graphic/74393.html" rel="external">picture 1A-F</a>). Pseudovesiculation and pustule formation are often present. Bullous Sweet syndrome and subcutaneous Sweet syndrome are less common manifestations. (See <a class="local">'Cutaneous'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated clinical and laboratory findings </strong>– Fever, malaise, joint pain, and muscle pain often accompany the cutaneous lesions. Involvement of internal organs may also occur. Leukocytosis and elevations in the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level are common laboratory findings. (See <a class="local">'Associated symptoms'</a> above and <a class="local">'Extracutaneous disease'</a> above and <a class="local">'Associated laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– A diagnosis of Sweet syndrome is made based upon both clinical and laboratory findings  (<a class="graphic graphic_table graphicRef85940" href="/d/graphic/85940.html" rel="external">table 1</a>). Biopsies characteristically demonstrate a dense neutrophilic infiltrate in the dermis without vasculitis. (See <a class="local">'Diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">SWEET RD. AN ACUTE FEBRILE NEUTROPHILIC DERMATOSIS. Br J Dermatol 1964; 76:349.</a></li><li><a class="nounderline abstract_t">Cohen PR. Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007; 2:34.</a></li><li><a class="nounderline abstract_t">Lallas A, Tzellos TG, Papageorgiou M, Mandekou-Lefaki I. Sweet's syndrome associated with upper respiratory tract streptococcal infection: "wait-and-see" strategy or anecdotal use of corticosteroids? Hippokratia 2011; 15:283.</a></li><li><a class="nounderline abstract_t">Ytting H, Vind I, Bang D, Munkholm P. Sweet's syndrome--an extraintestinal manifestation in inflammatory bowel disease. Digestion 2005; 72:195.</a></li><li><a class="nounderline abstract_t">Satra K, Zalka A, Cohen PR, Grossman ME. Sweet's syndrome and pregnancy. J Am Acad Dermatol 1994; 30:297.</a></li><li class="breakAll">Cohen PR, Hongsmann H, Kurzrock R. Acute febrile neutrophilic dermatosis (Sweet syndrome). In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al. (Eds), McGraw Hill, 2012. Vol 1, p.362.</li><li><a class="nounderline abstract_t">Gray PE, Bock V, Ziegler DS, Wargon O. Neonatal Sweet syndrome: a potential marker of serious systemic illness. Pediatrics 2012; 129:e1353.</a></li><li><a class="nounderline abstract_t">Sterling D, Duncan ME, Philippidou M, et al. VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist. J Am Acad Dermatol 2023; 89:1209.</a></li><li><a class="nounderline abstract_t">Cohen PR, Kurzrock R. Sweet's syndrome and cancer. Clin Dermatol 1993; 11:149.</a></li><li><a class="nounderline abstract_t">Halpern J, Salim A. Pediatric sweet syndrome: case report and literature review. Pediatr Dermatol 2009; 26:452.</a></li><li><a class="nounderline abstract_t">Bourke JF, Keohane S, Long CC, et al. Sweet's syndrome and malignancy in the U.K. Br J Dermatol 1997; 137:609.</a></li><li><a class="nounderline abstract_t">Raza S, Kirkland RS, Patel AA, et al. Insight into Sweet's syndrome and associated-malignancy: a review of the current literature. Int J Oncol 2013; 42:1516.</a></li><li><a class="nounderline abstract_t">Uihlein LC, Brandling-Bennett HA, Lio PA, Liang MG. Sweet syndrome in children. Pediatr Dermatol 2012; 29:38.</a></li><li><a class="nounderline abstract_t">Krilov LR, Jacobson M, Shende A. Acute febrile neutrophilic dermatosis (Sweet's syndrome) presenting as facial cellulitis in a child with juvenile chronic myelogenous leukemia. Pediatr Infect Dis J 1987; 6:77.</a></li><li><a class="nounderline abstract_t">Miranda CV, Filgueiras Fde M, Obadia DL, et al. Sweet's Syndrome associated with Hodgkin's disease: case report. An Bras Dermatol 2011; 86:1016.</a></li><li><a class="nounderline abstract_t">Wawrzycki B, Chodorowska G, Pietrzak A, et al. Recurrent skin eruption in patient with chronic lymphocytic leukemia and lymphocytic infiltrates of the dermis resembling Sweet's syndrome. G Ital Dermatol Venereol 2011; 146:487.</a></li><li><a class="nounderline abstract_t">Ravaglia C, Poletti G, Gurioli C, et al. Sweet's syndrome associated with myelogenous leukemia and pulmonary involvement. Monaldi Arch Chest Dis 2011; 75:149.</a></li><li><a class="nounderline abstract_t">Shugarman IL, Schmit JM, Sbicca JA, Wirk B. Easily missed extracutaneous manifestation of malignancy-associated Sweet's syndrome: systemic inflammatory response syndrome. J Clin Oncol 2011; 29:e702.</a></li><li><a class="nounderline abstract_t">Kato T, Kawana S, Takezaki S, et al. Case of Sweet's syndrome with extensive necrosis and ulcers accompanied by myelodysplastic syndrome. J Nippon Med Sch 2008; 75:162.</a></li><li><a class="nounderline abstract_t">Glendenning J, Khoo V. Sweet's syndrome in prostate cancer. Prostate Cancer Prostatic Dis 2008; 11:397.</a></li><li><a class="nounderline abstract_t">Awan F, Hamadani M, Devine S. Paraneoplastic Sweet's syndrome and the pathergy phenomenon. Ann Hematol 2007; 86:613.</a></li><li><a class="nounderline abstract_t">Culp L, Crowder S, Hatch S. A rare association of Sweet's syndrome with cervical cancer. Gynecol Oncol 2004; 95:396.</a></li><li><a class="nounderline abstract_t">Dereure O, Ebrard-Charra S, Guillon F, et al. Sweet's syndrome associated with pheochromocytoma. Dermatology 2004; 208:175.</a></li><li><a class="nounderline abstract_t">Liu D, Seiter K, Mathews T, et al. Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. Leuk Res 2004; 28 Suppl 1:S61.</a></li><li><a class="nounderline abstract_t">Gille J, Spieth K, Kaufmann R. Sweet's syndrome as initial presentation of diffuse large B-cell lymphoma. J Am Acad Dermatol 2002; 46:S11.</a></li><li><a class="nounderline abstract_t">Zappasodi P, Corso A, del Forno C. Sweet's syndrome and myelodysplasia: two entities with a common pathogenetic mechanism? A case report. Haematologica 2000; 85:868.</a></li><li><a class="nounderline abstract_t">Suvajdzić N, Dimcić Z, Cvijetić O, Colović M. Sweet's syndrome associated with Hodgkin's disease. Haematologia (Budap) 1998; 29:157.</a></li><li><a class="nounderline abstract_t">Aubin F, Dufour MP, Angonin R, et al. Sweet's syndrome associated with cutaneous T cell lymphoma. Eur J Dermatol 1998; 8:178.</a></li><li><a class="nounderline abstract_t">Cho KH, Han KH, Kim SW, et al. Neutrophilic dermatoses associated with myeloid malignancy. Clin Exp Dermatol 1997; 22:269.</a></li><li><a class="nounderline abstract_t">Lear JT, Byrne JP. Bullous pyoderma gangrenosum, Sweet's syndrome and malignancy. Br J Dermatol 1997; 136:296.</a></li><li><a class="nounderline abstract_t">Deguchi M, Tsunoda T, Yuda F, Tagami H. Sweet's syndrome in acute myelogenous leukemia showing dermal infiltration of leukemic cells. Dermatology 1997; 194:182.</a></li><li><a class="nounderline abstract_t">Woodrow SL, Munn SE, Basarab T, Russel Jones R. Sweet's syndrome in association with non-Hodgkin's lymphoma. Clin Exp Dermatol 1996; 21:357.</a></li><li><a class="nounderline abstract_t">Colović MD, Janković GM, Novak AZ, et al. Sweet's syndrome associated with paracentric inversion of chromosome 3q in a patient with multiple myeloma. Eur J Haematol 1996; 57:188.</a></li><li><a class="nounderline abstract_t">Heer-Sonderhoff AH, Arning M, Wehmeier A, et al. Neutrophilic dermal infiltrates in granulocytopenic patients with acute leukemia. Ann Hematol 1995; 71:257.</a></li><li><a class="nounderline abstract_t">Shirono K, Kiyofuji C, Tsuda H. Sweet's syndrome in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid. Int J Hematol 1995; 62:183.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Furuse Y, Nishioka K. Sweet's syndrome with small cell carcinoma of the lung. J Dermatol 1994; 21:125.</a></li><li><a class="nounderline abstract_t">van Kamp H, van den Berg E, Timens W, et al. Sweet's syndrome in myeloid malignancy: a report of two cases. Br J Haematol 1994; 86:415.</a></li><li><a class="nounderline abstract_t">Inanç SE, Altum M, Onat H, Erseven G. Sweet's syndrome and Hodgkin's disease. Acta Oncol 1994; 33:574.</a></li><li><a class="nounderline abstract_t">Barnadas MA, Sitjàs D, Brunet S, et al. Acute febrile neutrophilic dermatosis (Sweet's syndrome) associated with prostate adenocarcinoma and a myelodysplastic syndrome. Int J Dermatol 1992; 31:647.</a></li><li><a class="nounderline abstract_t">Kramers C, Raemaekers JM, van Baar HM, et al. Sweet's syndrome as the presenting symptom of hairy cell leukemia with concomitant infection by Mycobacterium kansasii. Ann Hematol 1992; 65:55.</a></li><li><a class="nounderline abstract_t">Torralbo A, Herrero JA, del-Rio E, et al. Sweet's syndrome associated with multiple myeloma. Int J Dermatol 1992; 31:297.</a></li><li><a class="nounderline abstract_t">Uchida H, Ikari Y, Hashizume S, et al. A case of Sweet's syndrome with early gastric cancer. Dermatologica 1990; 181:224.</a></li><li><a class="nounderline abstract_t">Fischer G, Commens C, Bradstock K. Sweet's syndrome in hairy cell leukemia. J Am Acad Dermatol 1989; 21:573.</a></li><li><a class="nounderline abstract_t">Tuncer AM. Acute lymphoblastic leukemia and Sweet's syndrome. Acta Haematol 1988; 80:224.</a></li><li><a class="nounderline abstract_t">Visani G, Patrizi AL, Ricci P, et al. Sweet's syndrome: association with accelerated phase of chronic myeloid leukemia. Acta Haematol 1988; 79:207.</a></li><li><a class="nounderline abstract_t">Nguyen KQ, Hurst CG, Pierson DL, Rodman OG. Sweet's syndrome and ovarian carcinoma. Cutis 1983; 32:152.</a></li><li><a class="nounderline abstract_t">Marcoval J, Martín-Callizo C, Valentí-Medina F, et al. Sweet syndrome: long-term follow-up of 138 patients. Clin Exp Dermatol 2016; 41:741.</a></li><li><a class="nounderline abstract_t">Rochet NM, Chavan RN, Cappel MA, et al. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol 2013; 69:557.</a></li><li><a class="nounderline abstract_t">Nelson CA, Noe MH, McMahon CM, et al. Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol 2018; 78:303.</a></li><li><a class="nounderline abstract_t">Cohen PR, Talpaz M, Kurzrock R. Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol 1988; 6:1887.</a></li><li><a class="nounderline abstract_t">Cohen PR, Holder WR, Tucker SB, et al. Sweet syndrome in patients with solid tumors. Cancer 1993; 72:2723.</a></li><li><a class="nounderline abstract_t">Ghoufi L, Ortonne N, Ingen-Housz-Oro S, et al. Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant: A Comparative Series of 62 Patients. Medicine (Baltimore) 2016; 95:e3033.</a></li><li><a class="nounderline abstract_t">Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol 1996; 34:918.</a></li><li><a class="nounderline abstract_t">Su WP, Liu HN. Diagnostic criteria for Sweet's syndrome. Cutis 1986; 37:167.</a></li><li><a class="nounderline abstract_t">Magro CM, De Moraes E, Burns F. Sweet's syndrome in the setting of CD34-positive acute myelogenous leukemia treated with granulocyte colony stimulating factor: evidence for a clonal neutrophilic dermatosis. J Cutan Pathol 2001; 28:90.</a></li><li><a class="nounderline abstract_t">White JM, Mufti GJ, Salisbury JR, du Vivier AW. Cutaneous manifestations of granulocyte colony-stimulating factor. Clin Exp Dermatol 2006; 31:206.</a></li><li><a class="nounderline abstract_t">Treton X, Joly F, Alves A, et al. Azathioprine-induced Sweet's syndrome in Crohn's disease. Inflamm Bowel Dis 2008; 14:1757.</a></li><li><a class="nounderline abstract_t">Juanola X, Nolla JM, Servitje O, Valverde J. Hydralazine induced lupus and Sweet's syndrome. J Rheumatol 1991; 18:948.</a></li><li><a class="nounderline abstract_t">Thibault MJ, Billick RC, Srolovitz H. Minocycline-induced Sweet's syndrome. J Am Acad Dermatol 1992; 27:801.</a></li><li><a class="nounderline abstract_t">Mensing H, Kowalzick L. Acute febrile neutrophilic dermatosis (Sweet's syndrome) caused by minocycline. Dermatologica 1991; 182:43.</a></li><li><a class="nounderline abstract_t">Park CJ, Bae YD, Choi JY, et al. Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid. Korean J Intern Med 2001; 16:218.</a></li><li><a class="nounderline abstract_t">Arun B, Berberian B, Azumi N, et al. Sweet's syndrome during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia. Leuk Lymphoma 1998; 31:613.</a></li><li><a class="nounderline abstract_t">Kyllo RL, Parker MK, Rosman I, Musiek AC. Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma. J Am Acad Dermatol 2014; 70:e85.</a></li><li><a class="nounderline abstract_t">Yorio JT, Mays SR, Ciurea AM, et al. Case of vemurafenib-induced Sweet's syndrome. J Dermatol 2014; 41:817.</a></li><li><a class="nounderline abstract_t">Pattanaprichakul P, Tetzlaff MT, Lapolla WJ, et al. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol 2014; 41:326.</a></li><li><a class="nounderline abstract_t">Dickson EL, Bakhru A, Chan MP. Topotecan-induced Sweet's syndrome: A case report. Gynecol Oncol Case Rep 2013; 4:50.</a></li><li><a class="nounderline abstract_t">Zobniw CM, Saad SA, Kostoff D, Barthel BG. Bortezomib-induced Sweet's syndrome confirmed by rechallenge. Pharmacotherapy 2014; 34:e18.</a></li><li><a class="nounderline abstract_t">Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res 2013; 23:498.</a></li><li><a class="nounderline abstract_t">Kolb-Mäurer A, Kneitz H, Goebeler M. Sweet-like syndrome induced by bortezomib. J Dtsch Dermatol Ges 2013; 11:1200.</a></li><li><a class="nounderline abstract_t">Ravi V, Maloney NJ, Worswick S. Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review. Dermatol Ther 2019; 32:e13074.</a></li><li><a class="nounderline abstract_t">Kim MJ, Choe YH. EPONYM. Sweet syndrome. Eur J Pediatr 2010; 169:1439.</a></li><li><a class="nounderline abstract_t">Voelter-Mahlknecht S, Bauer J, Metzler G, et al. Bullous variant of Sweet's syndrome. Int J Dermatol 2005; 44:946.</a></li><li><a class="nounderline abstract_t">Escallier F, Gaudard S, Courtois JM, et al. [Sweet's syndrome and Yersinia enterocolitica infection]. Ann Dermatol Venereol 1990; 117:858.</a></li><li><a class="nounderline abstract_t">O'Connor Reina C, Garcia Iriarte MT, Rodriguez Diaz A, et al. Tonsil cancer and Sweet's syndrome. Otolaryngol Head Neck Surg 1998; 119:709.</a></li><li><a class="nounderline abstract_t">Kawakami T, Ohashi S, Kawa Y, et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol 2004; 140:570.</a></li><li><a class="nounderline abstract_t">Shinojima Y, Toma Y, Terui T. Sweet syndrome associated with intrahepatic cholangiocarcinoma producing granulocyte colony-stimulating factor. Br J Dermatol 2006; 155:1103.</a></li><li><a class="nounderline abstract_t">Tanaka N, Fujioka A, Tajima S, et al. Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Dermatol 2000; 143:728.</a></li><li><a class="nounderline abstract_t">Reuss-Borst MA, Müller CA, Waller HD. The possible role of G-CSF in the pathogenesis of Sweet's syndrome. Leuk Lymphoma 1994; 15:261.</a></li><li><a class="nounderline abstract_t">Loraas A, Waage A, Lamvik J. Cytokine response pattern in Sweet's syndrome associated with myelodysplasia. Br J Haematol 1994; 87:669.</a></li><li><a class="nounderline abstract_t">Reuss-Borst MA, Pawelec G, Saal JG, et al. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol 1993; 84:356.</a></li><li><a class="nounderline abstract_t">Giasuddin AS, El-Orfi AH, Ziu MM, El-Barnawi NY. Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol 1998; 39:940.</a></li><li><a class="nounderline abstract_t">Mijovic A, Novak A, Medenica L. Sweet's syndrome associated with inversion of chromosome 3q in a patient with refractory anemia. Eur J Haematol 1992; 49:156.</a></li><li><a class="nounderline abstract_t">Billström R, Heim S, Kristoffersson U, et al. Structural chromosomal abnormalities of 3q in myelodysplastic syndrome/acute myeloid leukaemia with Sweet's syndrome. Eur J Haematol 1990; 45:150.</a></li><li><a class="nounderline abstract_t">Kemmett D, Harrison DJ, Hunter JA. Antibodies to neutrophil cytoplasmic antigens: serologic marker for Sweet's syndrome. J Am Acad Dermatol 1991; 24:967.</a></li><li><a class="nounderline abstract_t">Takahama H, Kanbe T. Neutrophilic dermatosis of the dorsal hands: a case showing HLA B54, the marker of Sweet's syndrome. Int J Dermatol 2010; 49:1079.</a></li><li><a class="nounderline abstract_t">Mizoguchi M, Matsuki K, Mochizuki M, et al. Human leukocyte antigen in Sweet's syndrome and its relationship to Behçet's disease. Arch Dermatol 1988; 124:1069.</a></li><li><a class="nounderline abstract_t">Jo T, Horio K, Migita K. Sweet's syndrome in patients with MDS and MEFV mutations. N Engl J Med 2015; 372:686.</a></li><li><a class="nounderline abstract_t">von den Driesch P, Weber MF. Are antibodies to neutrophilic cytoplasmic antigens (ANCA) a serologic marker for Sweet's syndrome? J Am Acad Dermatol 1993; 29:666.</a></li><li class="breakAll">Moschella SL, Davis M. Neutrophilic dermatoses. In: Dermatology, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Elsevier, 2008. Vol 1, p.379.</li><li><a class="nounderline abstract_t">Guhl G, García-Díez A. Subcutaneous sweet syndrome. Dermatol Clin 2008; 26:541.</a></li><li><a class="nounderline abstract_t">Cohen PR. Subcutaneous Sweet's syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis. J Am Acad Dermatol 2005; 52:927.</a></li><li><a class="nounderline abstract_t">Walling HW, Snipes CJ, Gerami P, Piette WW. The relationship between neutrophilic dermatosis of the dorsal hands and sweet syndrome: report of 9 cases and comparison to atypical pyoderma gangrenosum. Arch Dermatol 2006; 142:57.</a></li><li><a class="nounderline abstract_t">Kroshinsky D, Alloo A, Rothschild B, et al. Necrotizing Sweet syndrome: a new variant of neutrophilic dermatosis mimicking necrotizing fasciitis. J Am Acad Dermatol 2012; 67:945.</a></li><li><a class="nounderline abstract_t">Sanchez IM, Lowenstein S, Johnson KA, et al. Clinical Features of Neutrophilic Dermatosis Variants Resembling Necrotizing Fasciitis. JAMA Dermatol 2019; 155:79.</a></li><li><a class="nounderline abstract_t">Surovy AM, Pelivani N, Hegyi I, et al. Giant cellulitis-like Sweet Syndrome, a new variant of neutrophilic dermatosis. JAMA Dermatol 2013; 149:79.</a></li><li><a class="nounderline abstract_t">Bamelis M, Boyden B, Sente F, Madoe V. Sweet's syndrome and acute myelogenous leukemia in a patient who presented with a sudden massive swelling of the tongue. Dermatology 1995; 190:335.</a></li><li><a class="nounderline abstract_t">Gottlieb CC, Mishra A, Belliveau D, et al. Ocular involvement in acute febrile neutrophilic dermatosis (Sweet syndrome): new cases and review of the literature. Surv Ophthalmol 2008; 53:219.</a></li><li><a class="nounderline abstract_t">Medenblik-Frysch S, von den Driesch P, Jonas JB, Meythaler FH. Ocular complications in Sweet's syndrome. Am J Ophthalmol 1992; 114:230.</a></li><li><a class="nounderline abstract_t">Vanourny J, Swick BL. Sweet syndrome with systemic inflammatory response syndrome. Arch Dermatol 2012; 148:969.</a></li><li><a class="nounderline abstract_t">Sawicki J, Morton RA, Ellis AK. Sweet syndrome with associated systemic inflammatory response syndrome: an ultimately fatal case. Ann Allergy Asthma Immunol 2010; 105:321.</a></li><li><a class="nounderline abstract_t">Otheo E, Ros P, Vázquez JL, et al. Systemic inflammatory response syndrome associated with Sweet's syndrome. Pediatr Crit Care Med 2002; 3:190.</a></li><li><a class="nounderline abstract_t">von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol 1994; 31:535.</a></li><li class="breakAll">Weedon D. The vasculopathic reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.195.</li><li><a class="nounderline abstract_t">Malone JC, Slone SP, Wills-Frank LA, et al. Vascular inflammation (vasculitis) in sweet syndrome: a clinicopathologic study of 28 biopsy specimens from 21 patients. Arch Dermatol 2002; 138:345.</a></li><li><a class="nounderline abstract_t">Lin J, Zhang Q, Chen M. Subcutaneous histiocytoid Sweet's syndrome in a patient associated with myelodysplastic syndrome-refractory anemia. J Dermatol 2012; 39:99.</a></li><li><a class="nounderline abstract_t">Kaiser R, Connolly K, Linker C, et al. Stem cell transplant for myelodysplastic syndrome-associated histiocytoid Sweet's syndrome in a patient with arthritis and myalgias. Arthritis Rheum 2008; 59:1832.</a></li><li><a class="nounderline abstract_t">Spencer B, Nanavati A, Greene J, Butler DF. Dapsone-responsive histiocytoid Sweet's syndrome associated with Crohn's disease. J Am Acad Dermatol 2008; 59:S58.</a></li><li><a class="nounderline abstract_t">Wu AJ, Rodgers T, Fullen DR. Drug-associated histiocytoid Sweet's syndrome: a true neutrophilic maturation arrest variant. J Cutan Pathol 2008; 35:220.</a></li><li><a class="nounderline abstract_t">Chow S, Pasternak S, Green P, et al. Histiocytoid neutrophilic dermatoses and panniculitides: variations on a theme. Am J Dermatopathol 2007; 29:334.</a></li><li><a class="nounderline abstract_t">Alegría-Landa V, Rodríguez-Pinilla SM, Santos-Briz A, et al. Clinicopathologic, Immunohistochemical, and Molecular Features of Histiocytoid Sweet Syndrome. JAMA Dermatol 2017; 153:651.</a></li><li><a class="nounderline abstract_t">Requena L, Kutzner H, Palmedo G, et al. Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes. Arch Dermatol 2005; 141:834.</a></li><li><a class="nounderline abstract_t">Chavan RN, Cappel MA, Ketterling RP, et al. Histiocytoid Sweet syndrome may indicate leukemia cutis: a novel application of fluorescence in situ hybridization. J Am Acad Dermatol 2014; 70:1021.</a></li><li><a class="nounderline abstract_t">Wasson S, Govindarajan G, Folzenlogen D. Concurrent occurrence of Sweet's syndrome and erythema nodosum: an overlap in the spectrum of reactive dermatoses. Clin Rheumatol 2006; 25:268.</a></li><li><a class="nounderline abstract_t">Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18:19.</a></li><li><a class="nounderline abstract_t">Gainon J, Bart PA, Waeber G. [Can we predict the risk of malignancy associated with dermatomyositis?]. Praxis (Bern 1994) 2003; 92:1734.</a></li></ol></div><div id="topicVersionRevision">Topic 13784 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14201182" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : AN ACUTE FEBRILE NEUTROPHILIC DERMATOSIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17655751" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22435036" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sweet's syndrome associated with upper respiratory tract streptococcal infection: "wait-and-see" strategy or anecdotal use of corticosteroids?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16179788" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sweet's syndrome--an extraintestinal manifestation in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8294585" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sweet's syndrome and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8294585" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sweet's syndrome and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508923" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neonatal Sweet syndrome: a potential marker of serious systemic illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35121074" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8339190" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sweet's syndrome and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19689524" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pediatric sweet syndrome: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390341" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sweet's syndrome and malignancy in the U.K.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23546524" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Insight into Sweet's syndrome and associated-malignancy: a review of the current literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22011318" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sweet syndrome in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3469614" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Acute febrile neutrophilic dermatosis (Sweet's syndrome) presenting as facial cellulitis in a child with juvenile chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147047" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Sweet's Syndrome associated with Hodgkin's disease: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22095180" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recurrent skin eruption in patient with chronic lymphocytic leukemia and lymphocytic infiltrates of the dermis resembling Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21932704" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sweet's syndrome associated with myelogenous leukemia and pulmonary involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21747081" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Easily missed extracutaneous manifestation of malignancy-associated Sweet's syndrome: systemic inflammatory response syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18648174" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Case of Sweet's syndrome with extensive necrosis and ulcers accompanied by myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18227857" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sweet's syndrome in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17468870" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Paraneoplastic Sweet's syndrome and the pathergy phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491764" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A rare association of Sweet's syndrome with cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15057014" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Sweet's syndrome associated with pheochromocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15036943" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807458" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sweet's syndrome as initial presentation of diffuse large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942935" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sweet's syndrome and myelodysplasia: two entities with a common pathogenetic mechanism? A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9728809" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sweet's syndrome associated with Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9649664" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Sweet's syndrome associated with cutaneous T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9604452" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Neutrophilic dermatoses associated with myeloid malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068763" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bullous pyoderma gangrenosum, Sweet's syndrome and malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9094473" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sweet's syndrome in acute myelogenous leukemia showing dermal infiltration of leukemic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9136156" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sweet's syndrome in association with non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8856100" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Sweet's syndrome associated with paracentric inversion of chromosome 3q in a patient with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7492629" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Neutrophilic dermal infiltrates in granulocytopenic patients with acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589363" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sweet's syndrome in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8182210" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sweet's syndrome with small cell carcinoma of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7515269" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sweet's syndrome in myeloid malignancy: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7917376" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Sweet's syndrome and Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1459765" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acute febrile neutrophilic dermatosis (Sweet's syndrome) associated with prostate adenocarcinoma and a myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1643163" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Sweet's syndrome as the presenting symptom of hairy cell leukemia with concomitant infection by Mycobacterium kansasii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1634301" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sweet's syndrome associated with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2176625" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A case of Sweet's syndrome with early gastric cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2674219" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sweet's syndrome in hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3146203" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Acute lymphoblastic leukemia and Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3132802" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sweet's syndrome: association with accelerated phase of chronic myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6617253" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sweet's syndrome and ovarian carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27663147" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sweet syndrome: long-term follow-up of 138 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23891394" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29107342" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3058878" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Malignancy-associated Sweet's syndrome: review of the world literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8402496" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sweet syndrome in patients with solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27082547" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant: A Comparative Series of 62 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8621829" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3514153" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Diagnostic criteria for Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168757" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sweet's syndrome in the setting of CD34-positive acute myelogenous leukemia treated with granulocyte colony stimulating factor: evidence for a clonal neutrophilic dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16487091" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cutaneous manifestations of granulocyte colony-stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18623176" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Azathioprine-induced Sweet's syndrome in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1895286" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hydralazine induced lupus and Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1469130" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Minocycline-induced Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1826487" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Acute febrile neutrophilic dermatosis (Sweet's syndrome) caused by minocycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11769583" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922053" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Sweet's syndrome during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24629370" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24617955" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Case of vemurafenib-induced Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24372055" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24371676" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Topotecan-induced Sweet's syndrome: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24338786" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bortezomib-induced Sweet's syndrome confirmed by rechallenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24113862" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23905772" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Sweet-like syndrome induced by bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31444856" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20445990" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : EPONYM. Sweet syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336530" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Bullous variant of Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2099706" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : [Sweet's syndrome and Yersinia enterocolitica infection].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9852556" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Tonsil cancer and Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15148101" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17034566" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Sweet syndrome associated with intrahepatic cholangiocarcinoma producing granulocyte colony-stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069448" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7532508" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The possible role of G-CSF in the pathogenesis of Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7527652" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cytokine response pattern in Sweet's syndrome associated with myelodysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7691149" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9843005" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1446734" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Sweet's syndrome associated with inversion of chromosome 3q in a patient with refractory anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2226727" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Structural chromosomal abnormalities of 3q in myelodysplastic syndrome/acute myeloid leukaemia with Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1869685" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Antibodies to neutrophil cytoplasmic antigens: serologic marker for Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20883277" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Neutrophilic dermatosis of the dorsal hands: a case showing HLA B54, the marker of Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3389850" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Human leukocyte antigen in Sweet's syndrome and its relationship to Behçet's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671271" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Sweet's syndrome in patients with MDS and MEFV mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8408813" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Are antibodies to neutrophilic cytoplasmic antigens (ANCA) a serologic marker for Sweet's syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8408813" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Are antibodies to neutrophilic cytoplasmic antigens (ANCA) a serologic marker for Sweet's syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18793988" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Subcutaneous sweet syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15858502" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Subcutaneous Sweet's syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16415387" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The relationship between neutrophilic dermatosis of the dorsal hands and sweet syndrome: report of 9 cases and comparison to atypical pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22445215" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Necrotizing Sweet syndrome: a new variant of neutrophilic dermatosis mimicking necrotizing fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383110" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Clinical Features of Neutrophilic Dermatosis Variants Resembling Necrotizing Fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23324762" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Giant cellulitis-like Sweet Syndrome, a new variant of neutrophilic dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7655121" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Sweet's syndrome and acute myelogenous leukemia in a patient who presented with a sudden massive swelling of the tongue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18501268" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Ocular involvement in acute febrile neutrophilic dermatosis (Sweet syndrome): new cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1642307" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Ocular complications in Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22911211" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Sweet syndrome with systemic inflammatory response syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20934634" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Sweet syndrome with associated systemic inflammatory response syndrome: an ultimately fatal case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12780994" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Systemic inflammatory response syndrome associated with Sweet's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8089280" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Sweet's syndrome (acute febrile neutrophilic dermatosis)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8089280" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Sweet's syndrome (acute febrile neutrophilic dermatosis)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11902985" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Vascular inflammation (vasculitis) in sweet syndrome: a clinicopathologic study of 28 biopsy specimens from 21 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22007966" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Subcutaneous histiocytoid Sweet's syndrome in a patient associated with myelodysplastic syndrome-refractory anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035416" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Stem cell transplant for myelodysplastic syndrome-associated histiocytoid Sweet's syndrome in a patient with arthritis and myalgias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625393" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Dapsone-responsive histiocytoid Sweet's syndrome associated with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18300386" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Drug-associated histiocytoid Sweet's syndrome: a true neutrophilic maturation arrest variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17667165" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Histiocytoid neutrophilic dermatoses and panniculitides: variations on a theme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28296991" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Clinicopathologic, Immunohistochemical, and Molecular Features of Histiocytoid Sweet Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027297" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24636890" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Histiocytoid Sweet syndrome may indicate leukemia cutis: a novel application of fluorescence in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15902518" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Concurrent occurrence of Sweet's syndrome and erythema nodosum: an overlap in the spectrum of reactive dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20880069" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14587367" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : [Can we predict the risk of malignancy associated with dermatomyositis?].</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
